Clinical trial · Interventional
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
A Randomized, Phase 2 Study Of FOLFOX Or FOLFIRI With AG-013736 Or Bevacizumab (Avastin) In Patients With Metastatic Colorectal Cancer After Failure Of An Irinotecan Or Oxaliplatin-Containing First-Line Regimen
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is designed to demonstrate that the combination of AG-013736 with either FOLFIRI or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab (Avastin) in delaying tumor progression in the second-line treatment of patients with metastatic colorectal cancer after failure of an irinotecan or oxaliplatin-containing first-line regimen.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Neoplasms | Colorectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AG-013736 (axitinib) | Drug | — | UNRESOLVED |
| Bevacizumab (avastin) | Drug | Bevacizumab | ALIAS |
| FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]) | Drug | FOLFIRI Regimen | ALIAS |
| FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]) | Drug | FOLFOX Regimen | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- ACTIVE_COMPARATOR
- label
- B
- description
- Bevacizumab (avastin)
- interventionNames
- Drug: Bevacizumab (avastin)
- Drug: FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])
- type
- EXPERIMENTAL
- label
- C
- description
- AG-013736 (axitinib)
- interventionNames
- Drug: AG-013736 (axitinib)
- Drug: FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])
- type
- EXPERIMENTAL
- label
- A
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically documented colorectal cancer plus one of the following: * Failure of one prior irinotecan- or oxaliplatin-containing regimen, or * Adjuvant refractory to irinotecan- or oxaliplatin-containing regimen. Exclusion Criteria: * Prior treatment in first line metastatic setting with more than one regimen * Prior irradiation of more than 25% of bone marrow.
References
Publications (0)
Data not yet available